Protective role of antibodies in enteric virus infections: Lessons from primary and secondary immune deficiencies.
Aichivirus
Parechovirus
Sapovirus
antibodies
enteric viruses
immune‐mediated hepatitis
norovirus
Journal
Immunological reviews
ISSN: 1600-065X
Titre abrégé: Immunol Rev
Pays: England
ID NLM: 7702118
Informations de publication
Date de publication:
28 Sep 2024
28 Sep 2024
Historique:
medline:
28
9
2024
pubmed:
28
9
2024
entrez:
28
9
2024
Statut:
aheadofprint
Résumé
Enteric viruses are the main cause of acute gastroenteritis worldwide with a significant morbidity and mortality, especially among children and aged adults. Some enteric viruses also cause disseminated infections and severe neurological manifestations such as poliomyelitis. Protective immunity against these viruses is not well understood in humans, with most knowledge coming from animal models, although the development of poliovirus and rotavirus vaccines has extended our knowledge. In a classical view, innate immunity involves the recognition of foreign DNA or RNA by pathogen recognition receptors leading to the production of interferons and other inflammatory cytokines. Antigen uptake and presentation to T cells and B cells then activate adaptive immunity and, in the case of the mucosal immunity, induce the secretion of dimeric IgA, the more potent immunoglobulins in viral neutralization. The study of Inborn errors of immunity (IEIs) offers a natural opportunity to study nonredundant immunity toward pathogens. In the case of enteric viruses, patients with a defective production of antibodies are at risk of developing neurological complications. Moreover, a recent description of patients with low or absent antibody production with protracted enteric viral infections associated with hepatitis reinforces the prominent role of B cells and immunoglobulins in the control of enteric virus.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Agence Nationale de Recherches sur le Sida et les Hépatites Virales
ID : ECTZ275762
Organisme : Agence Nationale de la Recherche
ID : ANR-10-IAHU-01
Organisme : Agence Nationale de la Recherche
ID : ANR-18-RHUS-0010
Organisme : Fondation pour la Recherche Médicale
ID : EQU202103012670
Informations de copyright
© 2024 The Author(s). Immunological Reviews published by John Wiley & Sons Ltd.
Références
Bishop RF, Kirkwood CD. Enteric viruses. Encyclopedia of Virology. Elsevier Science; 2008:116‐123. doi:10.1016/B978-012374410-4.00386-1
Ghosh S, Kumar M, Santiana M, et al. Enteric viruses replicate in salivary glands and infect through saliva. Nature. 2022;607(7918):345‐350. doi:10.1038/s41586-022-04895-8
Rhoades RE, Tabor‐Godwin JM, Tsueng G, Feuer R. Enterovirus infections of the central nervous system. Virology. 2011;411(2):288‐305. doi:10.1016/j.virol.2010.12.014
Ahmed SM, Hall AJ, Robinson AE, et al. Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta‐analysis. Lancet Infect Dis. 2014;14(8):725‐730. doi:10.1016/S1473-3099(14)70767-4
Crawford SE, Ramani S, Tate JE, et al. Rotavirus infection. Nat Rev Dis Primers. 2017;3:17083. doi:10.1038/nrdp.2017.83
Lundgren O, Svensson L. Pathogenesis of rotavirus diarrhea. Microbes Infect. 2001;3(13):1145‐1156. doi:10.1016/s1286-4579(01)01475-7
Oka T, Wang Q, Katayama K, Saif LJ. Comprehensive review of human sapoviruses. Clin Microbiol Rev. 2015;28(1):32‐53. doi:10.1128/CMR.00011-14
Cortez V, Meliopoulos VA, Karlsson EA, Hargest V, Johnson C, Schultz‐Cherry S. Astrovirus biology and pathogenesis. Annu Rev Virol. 2017;4(1):327‐348. doi:10.1146/annurev-virology-101416-041742
Kitajima M, Gerba C. Aichi virus 1: environmental occurrence and behavior. Pathogens. 2015;4(2):256‐268. doi:10.3390/pathogens4020256
Rivadulla E, Varela MF, Romalde JL. Epidemiology of Aichi virus in fecal samples from outpatients with acute gastroenteritis in Northwestern Spain. J Clin Virol. 2019;118:14‐19. doi:10.1016/j.jcv.2019.07.011
Bessaud M, Delpeyroux F. Enteroviruses‐the famous unknowns. Lancet Infect Dis. 2020;20(3):268‐269. doi:10.1016/S1473-3099(19)30636-X
Lockhart A, Mucida D, Parsa R. Immunity to enteric viruses. Immunity. 2022;55(5):800‐818. doi:10.1016/j.immuni.2022.04.007
Tangye SG, Al‐Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2022;42(7):1473‐1507. doi:10.1007/s10875-022-01289-3
Casanova JL, Peel J, Donadieu J, Neehus AL, Puel A, Bastard P. The ouroboros of autoimmunity. Nat Immunol. 2024;25(5):743‐754. doi:10.1038/s41590-024-01815-y
Jones TPW, Buckland M, Breuer J, Lowe DM. Viral infection in primary antibody deficiency syndromes. Rev Med Virol. 2019;29(4):e2049. doi:10.1002/rmv.2049
Bernard‐Raichon L, Cadwell K. Immunomodulation by enteric viruses. Annu Rev Virol. 2023;10(1):477‐502. doi:10.1146/annurev-virology-111821-112317
Webb LG, Fernandez‐Sesma A. RNA viruses and the cGAS‐STING pathway: reframing our understanding of innate immune sensing. Curr Opin Virol. 2022;53:101206. doi:10.1016/j.coviro.2022.101206
López S, Sánchez‐Tacuba L, Moreno J, Arias CF. Rotavirus strategies against the innate antiviral system. Annu Rev Virol. 2016;3(1):591‐609. doi:10.1146/annurev-virology-110615-042152
Ingle H, Peterson S, Baldridge M. Distinct effects of type I and III interferons on enteric viruses. Viruses. 2018;10(1):46. doi:10.3390/v10010046
Kalugotla G, Marmerstein V, Baldridge MT. Regulation of host/pathogen interactions in the gastrointestinal tract by type I and III interferons. Curr Opin Immunol. 2024;87:102425. doi:10.1016/j.coi.2024.102425
Zhang Q, Kisand K, Feng Y, et al. In search of a function for human type III interferons: insights from inherited and acquired deficits. Curr Opin Immunol. 2024;87:102427. doi:10.1016/j.coi.2024.102427
Crow YJ, Casanova JL. Human life within a narrow range: the lethal ups and downs of type I interferons. Sci Immunol. 2024;9(97):eadm8185. doi:10.1126/sciimmunol.adm8185
Casanova JL, Abel L. The microbe, the infection enigma, and the host. Annu Rev Microbiol. 2024;28. Published online. doi:10.1146/annurev-micro-092123-022855
Fischer A, Rausell A. Primary immunodeficiencies suggest redundancy within the human immune system. Sci Immunol. 2016;1(6):eaah5861. doi:10.1126/sciimmunol.aah5861
Pott J, Stockinger S, Torow N, et al. Age‐dependent TLR3 expression of the intestinal epithelium contributes to rotavirus susceptibility. PLoS Pathog. 2012;8(5):e1002670. doi:10.1371/journal.ppat.1002670
Atmar RL, Bernstein DI, Harro CD, et al. Norovirus vaccine against experimental human Norwalk virus illness. N Engl J Med. 2011;365(23):2178‐2187. doi:10.1056/NEJMoa1101245
Cheuvart B, Neuzil KM, Steele AD, et al. Association of serum anti‐rotavirus immunoglobulin A antibody seropositivity and protection against severe rotavirus gastroenteritis: analysis of clinical trials of human rotavirus vaccine. Hum Vaccin Immunother. 2014;10(2):505‐511. doi:10.4161/hv.27097
Lindesmith L, Moe C, Marionneau S, et al. Human susceptibility and resistance to Norwalk virus infection. Nat Med. 2003;9(5):548‐553. doi:10.1038/nm860
Nishio O, Sakae K, Ishihara Y, Isomura S, Inouye S. Adenovirus infection and specific secretory IgA responses in the intestine of infants. Microbiol Immunol. 1992;36(6):623‐631. doi:10.1111/j.1348-0421.1992.tb02062.x
Ramani S, Neill FH, Opekun AR, et al. Mucosal and cellular immune responses to Norwalk virus. J Infect Dis. 2015;212(3):397‐405. doi:10.1093/infdis/jiv053
Unicomb LE, Jarecki‐Khan K, Hall A, Podder G. Previous enteric adenovirus infection does not protect against subsequent symptomatic infection: longitudinal follow‐up of eight infants. Microbiol Immunol. 1996;40(2):161‐168. doi:10.1111/j.1348-0421.1996.tb03320.x
Blutt SE, Miller AD, Salmon SL, Metzger DW, Conner ME. IgA is important for clearance and critical for protection from rotavirus infection. Mucosal Immunol. 2012;5(6):712‐719. doi:10.1038/mi.2012.51
Fagarasan S, Kawamoto S, Kanagawa O, Suzuki K. Adaptive immune regulation in the gut: T cell‐dependent and T cell‐independent IgA synthesis. Annu Rev Immunol. 2010;28:243‐273. doi:10.1146/annurev-immunol-030409-101314
Lussier G, Smith AL, Guénette D, Descôteaux JP. Serological relationship between mouse adenovirus strains FL and K87. Lab Anim Sci. 1987;37(1):55‐57.
Wang Z, Lorenzi JCC, Muecksch F, et al. Enhanced SARS‐CoV‐2 neutralization by dimeric IgA. Sci Transl Med. 2021;13(577):eabf1555. doi:10.1126/scitranslmed.abf1555
Connor RI, Brickley EB, Wieland‐Alter WF, et al. Mucosal immunity to poliovirus. Mucosal Immunol. 2022;15(1):1‐9. doi:10.1038/s41385-021-00428-0
McNeal MM, Ward RL. Long‐term production of rotavirus antibody and protection against reinfection following a single infection of neonatal mice with murine rotavirus. Virology. 1995;211(2):474‐480. doi:10.1006/viro.1995.1429
Williams MB, Rosé JR, Rott LS, Franco MA, Greenberg HB, Butcher EC. The memory B cell subset responsible for the secretory IgA response and protective humoral immunity to rotavirus expresses the intestinal homing receptor, alpha4beta7. J Immunol. 1998;161(8):4227‐4235.
Hörnquist CE, Ekman L, Grdic KD, Schön K, Lycke NY. Paradoxical IgA immunity in CD4‐deficient mice. Lack of cholera toxin‐specific protective immunity despite normal gut mucosal IgA differentiation. J Immunol. 1995;155(6):2877‐2887.
Snider DP, Liang H, Switzer I, Underdown BJ. IgA production in MHC class II‐deficient mice is primarily a function of B‐1a cells. Int Immunol. 1999;11(2):191‐198. doi:10.1093/intimm/11.2.191
Chachu KA, Strong DW, LoBue AD, Wobus CE, Baric RS, Virgin HW. Antibody is critical for the clearance of murine norovirus infection. J Virol. 2008;82(13):6610‐6617. doi:10.1128/JVI.00141-08
Franco MA, Greenberg HB. Role of B cells and cytotoxic T lymphocytes in clearance of and immunity to rotavirus infection in mice. J Virol. 1995;69(12):7800‐7806. doi:10.1128/JVI.69.12.7800-7806.1995
Franco MA, Tin C, Greenberg HB. CD8+ T cells can mediate almost complete short‐term and partial long‐term immunity to rotavirus in mice. J Virol. 1997;71(5):4165‐4170. doi:10.1128/jvi.71.5.4165-4170.1997
Swamy M, Abeler‐Dörner L, Chettle J, et al. Intestinal intraepithelial lymphocyte activation promotes innate antiviral resistance. Nat Commun. 2015;6(1):7090. doi:10.1038/ncomms8090
Cifuente JO, Moratorio G. Evolutionary and structural overview of human picornavirus capsid antibody evasion. Front Cell Infect Microbiol. 2019;9:283. doi:10.3389/fcimb.2019.00283
Baggen J, Thibaut HJ, Strating JRPM, van Kuppeveld FJM. The life cycle of non‐polio enteroviruses and how to target it. Nat Rev Microbiol. 2018;16(6):368‐381. doi:10.1038/s41579-018-0005-4
Feng Z, Hensley L, McKnight KL, et al. A pathogenic picornavirus acquires an envelope by hijacking cellular membranes. Nature. 2013;496(7445):367‐371. doi:10.1038/nature12029
Bird SW, Maynard ND, Covert MW, Kirkegaard K. Nonlytic viral spread enhanced by autophagy components. Proc Natl Acad Sci U S A. 2014;111(36):13081‐13086. doi:10.1073/pnas.1401437111
Bucciol G, Moens L, Payne K, et al. Chronic Aichi virus infection in a patient with X‐linked agammaglobulinemia. J Clin Immunol. 2018;38(7):748‐752. doi:10.1007/s10875-018-0558-z
McKinney RE, Katz SL, Wilfert CM. Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. Rev Infect Dis. 1987;9(2):334‐356. doi:10.1093/clinids/9.2.334
Wilfert CM, Buckley RH, Mohanakumar T, et al. Persistent and fatal central‐nervous‐system ECHOvirus infections in patients with agammaglobulinemia. N Engl J Med. 1977;296(26):1485‐1489. doi:10.1056/NEJM197706302962601
Mena I, Perry CM, Harkins S, Rodriguez F, Gebhard J, Whitton JL. The role of B lymphocytes in coxsackievirus B3 infection. Am J Pathol. 1999;155(4):1205‐1215. doi:10.1016/S0002-9440(10)65223-6
Grant CFJ, Carr BV, Kotecha A, et al. The B cell response to foot‐and‐mouth disease virus in cattle following sequential vaccination with multiple serotypes. J Virol. 2017;91(9):e02157‐16. doi:10.1128/JVI.02157-16
Sun M, Li C, Xu W, et al. Immune serum from Sabin inactivated poliovirus vaccine immunization neutralizes multiple individual wild and vaccine‐derived polioviruses. Clin Infect Dis. 2017;64(10):1317‐1325. doi:10.1093/cid/cix110
Simon‐Loriere E, Holmes EC. Why do RNA viruses recombine? Nat Rev Microbiol. 2011;9(8):617‐626. doi:10.1038/nrmicro2614
Xie Z, Khamrin P, Maneekarn N, Kumthip K. Epidemiology of enterovirus genotypes in association with human diseases. Viruses. 2024;16(7):1165. doi:10.3390/v16071165
Chuang YY, Huang YC. Enteroviral infection in neonates. J Microbiol Immunol Infect. 2019;52(6):851‐857. doi:10.1016/j.jmii.2019.08.018
Hu K, Onintsoa Diarimalala R, Yao C, Li H, Wei Y. EV‐A71 mechanism of entry: receptors/Co‐receptors, related pathways and inhibitors. Viruses. 2023;15(3):785. doi:10.3390/v15030785
Lugo D, Krogstad P. Enteroviruses in the early 21st century: new manifestations and challenges. Curr Opin Pediatr. 2016;28(1):107‐113. doi:10.1097/MOP.0000000000000303
Messacar K, Schreiner TL, Maloney JA, et al. A cluster of acute flaccid paralysis and cranial nerve dysfunction temporally associated with an outbreak of enterovirus D68 in children in Colorado, USA. Lancet. 2015;385(9978):1662‐1671. doi:10.1016/S0140-6736(14)62457-0
Abedi GR, Watson JT, Pham H, Nix WA, Oberste MS, Gerber SI. Enterovirus and human Parechovirus surveillance – United States, 2009‐2013. MMWR Morb Mortal Wkly Rep. 2015;64(34):940‐943. doi:10.15585/mmwr.mm6434a3
Isaacs SR, Roy A, Dance B, et al. Enteroviruses and risk of islet autoimmunity or type 1 diabetes: systematic review and meta‐analysis of controlled observational studies detecting viral nucleic acids and proteins. Lancet Diabetes Endocrinol. 2023;11(8):578‐592. doi:10.1016/S2213-8587(23)00122-5
Rodriguez‐Calvo T. Enterovirus infection and type 1 diabetes: unraveling the crime scene. Clin Exp Immunol. 2019;195(1):15‐24. doi:10.1111/cei.13223
Bouin A, Gretteau PA, Wehbe M, et al. Enterovirus persistence in cardiac cells of patients with idiopathic dilated cardiomyopathy is linked to 5′ terminal genomic RNA‐deleted viral populations with viral‐encoded proteinase activities. Circulation. 2019;139(20):2326‐2338. doi:10.1161/CIRCULATIONAHA.118.035966
Halliday E. Enteroviral infections in primary immunodeficiency (PID): a survey of morbidity and mortality. J Infect. 2003;46(1):1‐8. doi:10.1053/jinf.2002.1066
Rudge P, Webster ADB, Revesz T, et al. Encephalomyelitis in primary hypogammaglobulinaemia. Brain. 1996;119(1):1‐15. doi:10.1093/brain/119.1.1
Winkelstein JA, Marino MC, Lederman HM, et al. X‐linked Agammaglobulinemia: report on a United States registry of 201 patients. Medicine. 2006;85(4):193‐202. doi:10.1097/01.md.0000229482.27398.ad
Lederman HM, Winkelstein JA. X‐linked agammaglobulinemia: an analysis of 96 patients. Medicine. 1985;64(3):145‐156.
NaserEddin A, Shamriz O, Keller B, et al. Enteroviral infection in a patient with BLNK adaptor protein deficiency. J Clin Immunol. 2015;35(4):356‐360. doi:10.1007/s10875-015-0164-2
Lopez Granados E, Porpiglia AS, Hogan MB, et al. Clinical and molecular analysis of patients with defects in micro heavy chain gene. J Clin Invest. 2002;110(7):1029‐1035. doi:10.1172/JCI15658
Oksenhendler E, Gérard L, Fieschi C, et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis. 2008;46(10):1547‐1554. doi:10.1086/587669
Malphettes M, Gérard L, Carmagnat M, et al. Late‐onset combined immune deficiency: a subset of common variable immunodeficiency with severe T cell defect. Clin Infect Dis. 2009;49(9):1329‐1338. doi:10.1086/606059
Micol R, Kayal S, Mahlaoui N, et al. Protective effect of IgM against colonization of the respiratory tract by nontypeable Haemophilus influenzae in patients with hypogammaglobulinemia. J Allergy Clin Immunol. 2012;129(3):770‐777. doi:10.1016/j.jaci.2011.09.047
Guo J, Bolivar‐Wagers S, Srinivas N, Holubar M, Maldonado Y. Immunodeficiency‐related vaccine‐derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication. Vaccine. 2015;33(10):1235‐1242. doi:10.1016/j.vaccine.2015.01.018
Fischer A, Notarangelo LD, Neven B, Cavazzana M, Puck JM. Severe combined immunodeficiencies and related disorders. Nat Rev Dis Primers. 2015;1:15061. doi:10.1038/nrdp.2015.61
Martin De Frémont G, Chabrolles H, Mirand A, et al. Severe enterovirus infections in patients with immune‐mediated inflammatory diseases receiving anti‐CD20 monoclonal antibodies. RMD Open. 2024;10(2):e004036. doi:10.1136/rmdopen-2023-004036
Sciandra I, Falasca F, Maida P, et al. Seroprevalence of group B Coxsackieviruses: retrospective study in an Italian population. J Med Virol. 2020;92(12):3138‐3143. doi:10.1002/jmv.26096
Planitzer CB, Farcet MR, Schiff RI, Ochs HD, Kreil TR. Neutralization of different echovirus serotypes by individual lots of intravenous immunoglobulin. J Med Virol. 2011;83(2):305‐310. doi:10.1002/jmv.21980
Onodera H, Nakagawa R, Nakagawa H, Urayama T, Haino K, Yunoki M. Long‐term monitoring of virus antibody titers in human intravenous immunoglobulin lots derived from donors in Japan. Transfusion. 2018;58(11):2617‐2626. doi:10.1111/trf.14908
Howard RS. Poliomyelitis and the postpolio syndrome. BMJ. 2005;330(7503):1314‐1318. doi:10.1136/bmj.330.7503.1314
Aylward B, Yamada T. The polio endgame. N Engl J Med. 2011;364(24):2273‐2275. doi:10.1056/NEJMp1104329
Arita M, Iwai M, Wakita T, Shimizu H. Development of a poliovirus neutralization test with poliovirus Pseudovirus for measurement of neutralizing antibody titer in human serum. Clin Vaccine Immunol. 2011;18(11):1889‐1894. doi:10.1128/CVI.05225-11
Brickley EB, Wieland‐Alter W, Connor RI, et al. Intestinal immunity to poliovirus following sequential trivalent inactivated polio vaccine/bivalent Oral polio vaccine and trivalent inactivated polio vaccine‐only immunization schedules: analysis of an open‐label, randomized, controlled trial in Chilean infants. Clin Infect Dis. 2018;67(Suppl 1):S42‐S50. doi:10.1093/cid/ciy603
Larocca AMV, Bianchi FP, Bozzi A, Tafuri S, Stefanizzi P, Germinario CA. Long‐term immunogenicity of inactivated and Oral polio vaccines: an Italian retrospective cohort study. Vaccine. 2022;10(8):1329. doi:10.3390/vaccines10081329
Wallace GS, Curns AT, Weldon WC, Oberste MS. Seroprevalence of poliovirus antibodies in the United States population, 2009–2010. BMC Public Health. 2016;16:721. doi:10.1186/s12889-016-3386-1
Cesario TC, Nakano JH, Caldwell GG, Youmans RA. Paralytic poliomyelitis in an unimmunized child. Apparent result of a vaccine‐derived poliovirus. Am J Dis Child. 1969;118(6):895‐898. doi:10.1001/archpedi.1969.02100040897015
Shaw EB, Cesario TC. Vaccine‐derived poliomyelitis. Am J Dis Child. 1970;119(6):546. doi:10.1001/archpedi.1970.02100050548017
Singanayagam A, Klapsa D, Burton‐Fanning S, et al. Asymptomatic immunodeficiency‐associated vaccine‐derived poliovirus infections in two UK children. Nat Commun. 2023;14(1):3413. doi:10.1038/s41467-023-39094-0
Wyatt HV. Poliomyelitis in hypogammaglobulinemics. J Infect Dis. 1973;128(6):802‐806. doi:10.1093/infdis/128.6.802
Platt LR, Estívariz CF, Sutter RW. Vaccine‐associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis. 2014;210(Suppl 1):S380‐S389. doi:10.1093/infdis/jiu184
Quartier P, Foray S, Casanova JL, Hau‐Rainsard I, Blanche S, Fischer A. Enteroviral meningoencephalitis in X‐linked agammaglobulinemia: intensive immunoglobulin therapy and sequential viral detection in cerebrospinal fluid by polymerase chain reaction. Pediatr Infect Dis J. 2000;19(11):1106‐1108. doi:10.1097/00006454-200011000-00020
Misbah SA, Spickett GP, Ryba PC, et al. Chronic enteroviral meningoencephalitis in agammaglobulinemia: case report and literature review. J Clin Immunol. 1992;12(4):266‐270. doi:10.1007/BF00918150
Barral PM, Morrison JM, Drahos J, et al. MDA‐5 is cleaved in poliovirus‐infected cells. J Virol. 2007;81(8):3677‐3684. doi:10.1128/JVI.01360-06
Neznanov N, Chumakov KM, Neznanova L, Almasan A, Banerjee AK, Gudkov AV. Proteolytic cleavage of the p65‐RelA subunit of NF‐kappaB during poliovirus infection. J Biol Chem. 2005;280(25):24153‐24158. doi:10.1074/jbc.M502303200
Luk ADW, Ni K, Wu Y, et al. Type I and III interferon productions are impaired in X‐linked Agammaglobulinemia patients toward poliovirus but not influenza virus. Front Immunol. 2018;9:1826. doi:10.3389/fimmu.2018.01826
Bubba L, Broberg EK, Fischer TK, Simmonds P, Harvala H. European non‐polio enterovirus network working group. Parechovirus A circulation and testing capacities in Europe, 2015–2021. Emerg Infect Dis. 2024;30(2):234‐244. doi:10.3201/eid3002.230647
Harvala H, Wolthers KC, Simmonds P. Parechoviruses in children: understanding a new infection. Curr Opin Infect Dis. 2010;23(3):224‐230. doi:10.1097/qco.0b013e32833890ca
Esposito S, Rahamat‐Langendoen J, Ascolese B, Senatore L, Castellazzi L, Niesters HGM. Pediatric parechovirus infections. J Clin Virol. 2014;60(2):84‐89. doi:10.1016/j.jcv.2014.03.003
Wolthers KC, Benschop KSM, Schinkel J, et al. Human parechoviruses as an important viral cause of sepsislike illness and meningitis in young children. Clin Infect Dis. 2008;47(3):358‐363. doi:10.1086/589752
Alshammari A, Alotaibi J, Almaghrabi R, Bawazeer R, Althawadi S, Tayeb H. First parechovirus reported case in Saudi Arabia in hospitalized immunocompromised adult patient. Virol J. 2024;21(1):102. doi:10.1186/s12985-024-02372-4
Van De Ven AA, Douma JW, Rademaker C, et al. Pleconaril‐resistant chronic Parechovirus‐associated enteropathy in Agammaglobulinaemia. Antivir Ther. 2011;16(4):611‐614. doi:10.3851/IMP1792
Couderé K, van der Straten K, Brouwer L, et al. Neutralising antibodies against enterovirus and Parechovirus in IVIG reflect general circulation: a tool for Sero‐surveillance. Viruses. 2021;13(6):1028. doi:10.3390/v13061028
Rivadulla E, Romalde JL. A comprehensive review on human Aichi virus. Virol Sin. 2020;35(5):501‐516. doi:10.1007/s12250-020-00222-5
Sabin C, Füzik T, Škubník K, Pálková L, Lindberg AM, Plevka P. Structure of Aichi virus 1 and its empty particle: clues to Kobuvirus genome release mechanism. J Virol. 2016;90(23):10800‐10810. doi:10.1128/JVI.01601-16
Zhu L, Wang X, Ren J, et al. Structure of human Aichi virus and implications for receptor binding. Nat Microbiol. 2016;1(11):16150. doi:10.1038/nmicrobiol.2016.150
Pham NTK, Khamrin P, Nguyen TA, et al. Isolation and molecular characterization of Aichi viruses from fecal specimens collected in Japan, Bangladesh, Thailand, and Vietnam. J Clin Microbiol. 2007;45(7):2287‐2288. doi:10.1128/JCM.00525-07
Ambert‐Balay K, Lorrot M, Bon F, et al. Prevalence and genetic diversity of Aichi virus strains in stool samples from community and hospitalized patients. J Clin Microbiol. 2008;46(4):1252‐1258. doi:10.1128/JCM.02140-07
Sdiri‐Loulizi K, Khachou A, Khelifi H, et al. Dynamics of norovirus genotype change and early characterization of variants in children with diarrhea in central Tunisia, 2001‐2012. Arch Virol. 2022;167(1):99‐107. doi:10.1007/s00705-021-05290-w
Kaikkonen S, Räsänen S, Rämet M, Vesikari T. Aichi virus infection in children with acute gastroenteritis in Finland. Epidemiol Infect. 2010;138(8):1166‐1171. doi:10.1017/S0950268809991300
Ribes JM, Montava R, Téllez‐Castillo CJ, Fernández‐Jiménez M, Buesa J. Seroprevalence of Aichi virus in a Spanish population from 2007 to 2008. Clin Vaccine Immunol. 2010;17(4):545‐549. doi:10.1128/CVI.00382-09
Sdiri‐Loulizi K, Hassine M, Bour JB, et al. Aichi virus IgG seroprevalence in Tunisia parallels genomic detection and clinical presentation in children with gastroenteritis. Clin Vaccine Immunol. 2010;17(7):1111‐1116. doi:10.1128/CVI.00059-10
Yamashita T, Ito M, Tsuzuki H, Sakae K. Identification of Aichi virus infection by measurement of immunoglobulin responses in an enzyme‐linked immunosorbent assay. J Clin Microbiol. 2001;39(11):4178‐4180. doi:10.1128/JCM.39.11.4178-4180.2001
Oh DY, Silva PA, Hauroeder B, Diedrich S, Cardoso DDP, Schreier E. Molecular characterization of the first Aichi viruses isolated in Europe and in South America. Arch Virol. 2006;151(6):1199‐1206. doi:10.1007/s00705-005-0706-7
Goyer M, Aho LS, Bour JB, Ambert‐Balay K, Pothier P. Seroprevalence distribution of Aichi virus among a French population in 2006‐2007. Arch Virol. 2008;153(6):1171‐1174. doi:10.1007/s00705-008-0091-0
Portes SAR, Volotao E d M, Rose TL, et al. Aichi virus positivity in HIV‐1 seropositive children hospitalized with diarrheal disease. Curr HIV Res. 2015;13(4):325‐331. doi:10.2174/1570162X13666150511145950
Meyts I, Bucciol G, Jansen K, Wollants E, Breuer J. Aichivirus: an emerging pathogen in patients with primary and secondary B‐cell deficiency. J Clin Immunol. 2023;43(3):532‐535. doi:10.1007/s10875-022-01410-6
Riller Q, Fourgeaud J, Bruneau J, et al. Late‐onset enteric virus infection associated with hepatitis (EVAH) in transplanted SCID patients. J Allergy Clin Immunol. 2023;151(6):1634‐1645. doi:10.1016/j.jaci.2022.12.822
Fourgeaud J, Lecuit MM, Pérot P, et al. Chronic Aichi virus infection as a cause of long‐lasting multi‐organ involvement in patients with primary immune deficiencies. Clin Infect Dis. 2023;77:ciad237. doi:10.1093/cid/ciad237
Bekassy Z, Ehinger M, Pronk LN, Pronk CJ, SMPOT Group. Immunologic control of disseminated Aichi virus infection in X‐linked Agammaglobulinemia by transplantation of TcRαβ‐depleted haploidentical hematopoietic cells. J Clin Immunol. 2022;42(7):1401‐1404. doi:10.1007/s10875-022-01314-5
Bosch A, Pintó RM, Guix S. Human Astroviruses. Clin Microbiol Rev. 2014;27(4):1048‐1074. doi:10.1128/CMR.00013-14
De Benedictis P, Schultz‐Cherry S, Burnham A, Cattoli G. Astrovirus infections in humans and animals – molecular biology, genetic diversity, and interspecies transmissions. Infect Genet Evol. 2011;11(7):1529‐1544. doi:10.1016/j.meegid.2011.07.024
Quan PL, Wagner TA, Briese T, et al. Astrovirus encephalitis in boy with X‐linked Agammaglobulinemia. Emerg Infect Dis. 2010;16(6):918‐925. doi:10.3201/eid1606.091536
Sato M, Kuroda M, Kasai M, et al. Acute encephalopathy in an immunocompromised boy with astrovirus‐MLB1 infection detected by next generation sequencing. J Clin Virol. 2016;78:66‐70. doi:10.1016/j.jcv.2016.03.010
Frémond ML, Pérot P, Muth E, et al. Next‐generation sequencing for diagnosis and tailored therapy: a case report of Astrovirus‐associated progressive encephalitis. J Pediatr Infect Dis Soc. 2015;4(3):e53‐e57. doi:10.1093/jpids/piv040
Brown JR, Morfopoulou S, Hubb J, et al. Astrovirus VA1/HMO‐C: an increasingly recognized neurotropic pathogen in immunocompromised patients. Clin Infect Dis. 2015;60(6):881‐888. doi:10.1093/cid/ciu940
Naccache SN, Peggs KS, Mattes FM, et al. Diagnosis of Neuroinvasive Astrovirus infection in an immunocompromised adult with encephalitis by unbiased next‐generation sequencing. Clin Infect Dis. 2015;60(6):919‐923. doi:10.1093/cid/ciu912
Wunderli W, Meerbach A, Guengoer T, et al. Astrovirus infection in hospitalized infants with severe combined immunodeficiency after allogeneic hematopoietic stem cell transplantation. PLoS One. 2011;6(11):e27483. doi:10.1371/journal.pone.0027483
Koukou G, Niendorf S, Hornei B, Schlump JU, Jenke AC, Jacobsen S. Human astrovirus infection associated with encephalitis in an immunocompetent child: a case report. J Med Case Reports. 2019;13(1):341. doi:10.1186/s13256-019-2302-6
Koopmans MPG, Bijen MHL, Monroe SS, Vinjé J. Age‐stratified Seroprevalence of neutralizing antibodies to Astrovirus types 1 to 7 in humans in The Netherlands. Clin Diagn Lab Immunol. 1998;5(1):33‐37. doi:10.1128/CDLI.5.1.33-37.1998
Mitchell DK, Matson DO, Cubitt WD, et al. Prevalence of antibodies to astrovirus types 1 and 3 in children and adolescents in Norfolk, Virginia. Pediatr Infect Dis J. 1999;18(3):249‐254. doi:10.1097/00006454-199903000-00008
Janowski AB, Owen MC, Dudley H, et al. High seropositivity rate of neutralizing antibodies to Astrovirus VA1 in human populations. mSphere. 2021;6(5):e00484‐21. doi:10.1128/mSphere.00484-21
Meyer L, Delgado‐Cunningham K, Lorig‐Roach N, Ford J, DuBois RM. Human Astrovirus 1‐8 Seroprevalence evaluation in a United States adult population. Viruses. 2021;13(6):979. doi:10.3390/v13060979
Vega E, Barclay L, Gregoricus N, Williams K, Lee D, Vinjé J. Novel surveillance network for norovirus gastroenteritis outbreaks, United States. Emerg Infect Dis. 2011;17(8):1389‐1395. doi:10.3201/eid1708.101837
Chhabra P, de Graaf M, Parra GI, et al. Updated classification of norovirus genogroups and genotypes. J Gen Virol. 2019;100(10):1393‐1406. doi:10.1099/jgv.0.001318
Prasad BV, Hardy ME, Dokland T, Bella J, Rossmann MG, Estes MK. X‐ray crystallographic structure of the Norwalk virus capsid. Science. 1999;286(5438):287‐290. doi:10.1126/science.286.5438.287
Kambhampati A, Payne DC, Costantini V, Lopman BA. Host genetic susceptibility to enteric viruses: a systematic review and metaanalysis. Clin Infect Dis. 2016;62(1):11‐18. doi:10.1093/cid/civ873
Jones MK, Watanabe M, Zhu S, et al. Enteric bacteria promote human and mouse norovirus infection of B cells. Science. 2014;346(6210):755‐759. doi:10.1126/science.1257147
de Graaf M, van Beek J, Koopmans MPG. Human norovirus transmission and evolution in a changing world. Nat Rev Microbiol. 2016;14(7):421‐433. doi:10.1038/nrmicro.2016.48
Costantini V, Morantz EK, Browne H, et al. Human norovirus replication in human intestinal enteroids as model to evaluate virus inactivation. Emerg Infect Dis. 2018;24(8):1453‐1464. doi:10.3201/eid2408.180126
Karst SM, Wobus CE. A working model of how noroviruses infect the intestine. PLoS Pathog. 2015;11(2):e1004626. doi:10.1371/journal.ppat.1004626
Brown LAK, Clark I, Brown JR, Breuer J, Lowe DM. Norovirus infection in primary immune deficiency. Rev Med Virol. 2017;27(3):e1926. doi:10.1002/rmv.1926
Newman KL, Moe CL, Kirby AE, Flanders WD, Parkos CA, Leon JS. Norovirus in symptomatic and asymptomatic individuals: cytokines and viral shedding. Clin Exp Immunol. 2016;184(3):347‐357. doi:10.1111/cei.12772
Ford‐Siltz LA, Tohma K, Parra GI. Understanding the relationship between norovirus diversity and immunity. Gut Microbes. 2021;13(1):1‐13. doi:10.1080/19490976.2021.1900994
Sapparapu G, Czakó R, Alvarado G, et al. Frequent use of the IgA isotype in human B cells encoding potent norovirus‐specific monoclonal antibodies that block HBGA binding. PLoS Pathog. 2016;12(6):e1005719. doi:10.1371/journal.ppat.1005719
Atmar RL, Opekun AR, Gilger MA, et al. Norwalk virus shedding after experimental human infection. Emerg Infect Dis. 2008;14(10):1553‐1557. doi:10.3201/eid1410.080117
Robilotti E, Deresinski S, Pinsky BA. Norovirus. Clin Microbiol Rev. 2015;28(1):134‐164. doi:10.1128/CMR.00075-14
Frange P, Touzot F, Debré M, et al. Prevalence and clinical impact of norovirus fecal shedding in children with inherited immune deficiencies. J Infect Dis. 2012;206(8):1269‐1274. doi:10.1093/infdis/jis498
Roddie C, Paul JPV, Benjamin R, et al. Allogeneic hematopoietic stem cell transplantation and norovirus gastroenteritis: a previously unrecognized cause of morbidity. Clin Infect Dis. 2009;49(7):1061‐1068. doi:10.1086/605557
Lemes LGN, Corrêa TS, Fiaccadori FS, et al. Prospective study on norovirus infection among allogeneic stem cell transplant recipients: prolonged viral excretion and viral RNA in the blood. J Clin Virol. 2014;61(3):329‐333. doi:10.1016/j.jcv.2014.08.004
Wingfield T, Gallimore CI, Xerry J, et al. Chronic norovirus infection in an HIV‐positive patient with persistent diarrhoea: a novel cause. J Clin Virol. 2010;49(3):219‐222. doi:10.1016/j.jcv.2010.07.025
Shillitoe BMJ, Ponsford M, Slatter MA, et al. Haematopoietic stem cell transplant for norovirus‐induced intestinal failure in X‐linked agammaglobulinemia. J Clin Immunol. 2021;41(7):1574‐1581. doi:10.1007/s10875-021-01088-2
Bok K, Green KY. Norovirus gastroenteritis in immunocompromised patients. N Engl J Med. 2013;368(10):971. doi:10.1056/NEJMc1301022
Petrignani M, Verhoef L, de Graaf M, Richardus JH, Koopmans M. Chronic sequelae and severe complications of norovirus infection: a systematic review of literature. J Clin Virol. 2018;105:1‐10. doi:10.1016/j.jcv.2018.05.004
Saif MA, Bonney DK, Bigger B, et al. Chronic norovirus infection in pediatric hematopoietic stem cell transplant recipients: a cause of prolonged intestinal failure requiring intensive nutritional support. Pediatr Transplant. 2011;15(5):505‐509. doi:10.1111/j.1399-3046.2011.01500.x
Roos‐Weil D, Ambert‐Balay K, Lanternier F, et al. Impact of norovirus/sapovirus‐related diarrhea in renal transplant recipients hospitalized for diarrhea. Transplantation. 2011;92(1):61‐69. doi:10.1097/TP.0b013e31821c9392
Malamut G, Verkarre V, Suarez F, et al. The enteropathy associated with common variable immunodeficiency: the delineated frontiers with celiac disease. Am J Gastroenterol. 2010;105(10):2262‐2275. doi:10.1038/ajg.2010.214
Woodward JM, Gkrania‐Klotsas E, Cordero‐Ng AY, et al. The role of chronic norovirus infection in the enteropathy associated with common variable immunodeficiency. Am J Gastroenterol. 2015;110(2):320‐327. doi:10.1038/ajg.2014.432
Strohmeier V, Andrieux G, Unger S, et al. Interferon‐driven immune dysregulation in common variable immunodeficiency‐associated villous atrophy and norovirus infection. J Clin Immunol. 2023;43(2):371‐390. doi:10.1007/s10875-022-01379-2
Madeley CR. Comparison of the features of Astroviruses and Caliciviruses seen in samples of feces by electron microscopy. J Infect Dis. 1979;139(5):519‐523. doi:10.1093/infdis/139.5.519
Hergens MP, Nederby Öhd J, Alm E, et al. Investigation of a food‐borne outbreak of gastroenteritis in a school canteen revealed a variant of sapovirus genogroup V not detected by standard PCR, Sollentuna, Sweden, 2016. Euro Surveill. 2017;22(22):30543. doi:10.2807/1560-7917.ES.2017.22.22.30543
Becker‐Dreps S, González F, Bucardo F. Sapovirus: an emerging cause of childhood diarrhea. Curr Opin Infect Dis. 2020;33(5):388‐397. doi:10.1097/QCO.0000000000000671
Madeley CR, Cosgrove BP. CALICIVIRUSES in man. The Lancet. 1976;307(7952):199‐200. doi:10.1016/S0140-6736(76)91309-X
Cubitt WD, Barrett ADT. Propagation of human candidate Calicivirus in cell culture. J Gen Virol. 1984;65(6):1123‐1126. doi:10.1099/0022-1317-65-6-1123
Hansman GS, Oka T, Katayama K, Takeda N. Enhancement of sapovirus recombinant capsid protein expression in insect cells. FEBS Lett. 2006;580(17):4047‐4050. doi:10.1016/j.febslet.2006.06.040
Oka T, Yamamoto M, Miyashita K, et al. Self‐assembly of sapovirus recombinant virus‐like particles from polyprotein in mammalian cells. Microbiol Immunol. 2009;53(1):49‐52. doi:10.1111/j.1348-0421.2008.00086.x
Euller‐Nicolas G, Le Mennec C, Schaeffer J, et al. Human Sapovirus replication in human intestinal Enteroids. J Virol. 2023;97(4):e0038323. doi:10.1128/jvi.00383-23
Matussek A, Dienus O, Djeneba O, Simpore J, Nitiema L, Nordgren J. Molecular characterization and genetic susceptibility of sapovirus in children with diarrhea in Burkina Faso. Infect Genet Evol. 2015;32:396‐400. doi:10.1016/j.meegid.2015.03.039
Bucardo F, Mallory ML, González F, et al. Charting the impact of maternal antibodies and repeat exposures on Sapovirus immunity in early childhood from a Nicaraguan birth cohort. J Infect Dis. 2024;jiae368. doi:10.1093/infdis/jiae368
Nakata S, Chiba S, Terashima H, Yokoyama T, Nakao T. Humoral immunity in infants with gastroenteritis caused by human Calicivirus. J Infect Dis. 1985;152(2):274‐279. doi:10.1093/infdis/152.2.274
Diez Valcarce M, Kambhampati AK, Calderwood LE, Hall AJ, Mirza SA, Vinjé J. Global distribution of sporadic sapovirus infections: a systematic review and meta‐analysis. PLoS One. 2021;16(8):e0255436. doi:10.1371/journal.pone.0255436
Sakai Y, Nakata S, Honma S, Tatsumi M, Numata‐Kinoshita K, Chiba S. Clinical severity of Norwalk virus and Sapporo virus gastroenteritis in children in Hokkaido, Japan. Pediatr Infect Dis J. 2001;20(9):849‐853. doi:10.1097/00006454-200109000-00005
Varela MF, Rivadulla E, Lema A, Romalde JL. Human Sapovirus among outpatients with acute gastroenteritis in Spain: a one‐year study. Viruses. 2019;11(2):144. doi:10.3390/v11020144
Schuster JE, Johnston SH, Piya B, et al. Infectious causes of acute gastroenteritis in US children undergoing allogeneic hematopoietic cell transplant: a longitudinal, multicenter study. J Pediatr Infect Dis Soc. 2020;9(4):421‐427. doi:10.1093/jpids/piz063
Daniel‐Wayman S, Fahle G, Palmore T, Green KY, Prevots DR. Norovirus, astrovirus, and sapovirus among immunocompromised patients at a tertiary care research hospital. Diagn Microbiol Infect Dis. 2018;92(2):143‐146. doi:10.1016/j.diagmicrobio.2018.05.017
Rippl M, Burkhard‐Meier A, Schönermarck U, Fischereder M. Sapovirus: an emerging pathogen in kidney transplant recipients? Infection. 2024 Published online. doi:10.1007/s15010-024-02242-9
Pietsch C, Liebert UG. Intrahost viral evolution during chronic sapovirus infections. J Clin Virol. 2019;113:1‐7. doi:10.1016/j.jcv.2019.02.001
Neres Silva T, Dábilla N, Santos Corrêa T, de Moraes AA, Souza M. Sapovirus detection and quantification in fecal samples from allogeneic hematopoietic stem cell transplant recipients. Virus. 2020;31(3):374‐377. doi:10.1007/s13337-020-00583-1
Attoui H, Mohd Jaafar F, de Micco P, de Lamballerie X. Coltiviruses and seadornaviruses in North America, Europe, and Asia. Emerg Infect Dis. 2005;11(11):1673‐1679. doi:10.3201/eid1111.050868
Dilcher M, Hasib L, Lechner M, et al. Genetic characterization of Tribeč virus and Kemerovo virus, two tick‐transmitted human‐pathogenic Orbiviruses. Virology. 2012;423(1):68‐76. doi:10.1016/j.virol.2011.11.020
Yamamoto SP, Motooka D, Egawa K, et al. Novel human reovirus isolated from children and its long‐term circulation with reassortments. Sci Rep. 2020;10(1):963. doi:10.1038/s41598-020-58003-9
Saxena K, Blutt SE, Ettayebi K, et al. Human intestinal Enteroids: a new model to study human rotavirus infection, host restriction, and pathophysiology. J Virol. 2016;90(1):43‐56. doi:10.1128/JVI.01930-15
Wong V. Acute gastroenteritis‐related encephalopathy. J Child Neurol. 2001;16(12):906‐910. doi:10.1177/088307380101601208
Nakagomi T, Nakagomi O. Rotavirus antigenemia in children with encephalopathy accompanied by rotavirus gastroenteritis. Arch Virol. 2005;150(9):1927‐1931. doi:10.1007/s00705-005-0565-2
Wong CJ, Price Z, Bruckner DA. Aseptic meningitis in an infant with rotavirus gastroenteritis. Pediatr Infect Dis. 1984;3(3):244‐246. doi:10.1097/00006454-198405000-00014
Ushijima H, Bosu K, Abe T, Shinozaki T. Suspected rotavirus encephalitis. Arch Dis Child. 1986;61(7):692‐694. doi:10.1136/adc.61.7.692
McCormack JG. Clinical features of rotavirus gastroenteritis. J Infect. 1982;4(2):167‐174. doi:10.1016/s0163-4453(82)93777-x
Salmi TT, Arstila P, Koivikko A. Central nervous system involvement in patients with rotavirus gastroenteritis. Scand J Infect Dis. 1978;10(1):29‐31. doi:10.3109/inf.1978.10.issue-1.06
Payne DC, Baggs J, Zerr DM, et al. Protective association between rotavirus vaccination and childhood seizures in the year following vaccination in US children. Clin Infect Dis. 2014;58(2):173‐177. doi:10.1093/cid/cit671
Angel J, Franco MA, Greenberg HB. Rotavirus immune responses and correlates of protection. Curr Opin Virol. 2012;2(4):419‐425. doi:10.1016/j.coviro.2012.05.003
Parra M, Herrera D, Jácome MF, et al. Circulating rotavirus‐specific T cells have a poor functional profile. Virology. 2014;468‐470:340‐350. doi:10.1016/j.virol.2014.08.020
Saulsbury FT, Winkelstein JA, Yolken RH. Chronic rotavirus infection in immunodeficiency. J Pediatr. 1980;97(1):61‐65. doi:10.1016/s0022-3476(80)80131-4
Kaplon J, Cros G, Ambert‐Balay K, et al. Rotavirus vaccine virus shedding, viremia and clearance in infants with severe combined immune deficiency. Pediatr Infect Dis J. 2015;34(3):326‐328. doi:10.1097/INF.0000000000000560
Patel NC, Hertel PM, Estes MK, et al. Vaccine‐acquired rotavirus in infants with severe combined immunodeficiency. N Engl J Med. 2010;362(4):314‐319. doi:10.1056/NEJMoa0904485
Conner ME, Blutt SE. The gastrointestinal frontier: IgA and viruses. Front Immunol. 2013;4:402. doi:10.3389/fimmu.2013.00402
Coulson BS, Grimwood K, Masendycz PJ, et al. Comparison of rotavirus immunoglobulin A coproconversion with other indices of rotavirus infection in a longitudinal study in childhood. J Clin Microbiol. 1990;28(6):1367‐1374. doi:10.1128/jcm.28.6.1367-1374.1990
Groome MJ, Koen A, Fix A, et al. Safety and immunogenicity of a parenteral P2‐VP8‐P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double‐blind, placebo‐controlled trial. Lancet Infect Dis. 2017;17(8):843‐853. doi:10.1016/S1473-3099(17)30242-6
Lion T. Adenovirus infections in immunocompetent and immunocompromised patients. Clin Microbiol Rev. 2014;27(3):441‐462. doi:10.1128/CMR.00116-13
Greber UF, Flatt JW. Adenovirus entry: from infection to immunity. Annu Rev Virol. 2019;6(1):177‐197. doi:10.1146/annurev-virology-092818-015550
Chang SY, Lee CN, Lin PH, et al. A community‐derived outbreak of adenovirus type 3 in children in Taiwan between 2004 and 2005. J Med Virol. 2008;80(1):102‐112. doi:10.1002/jmv.21045
Sandkovsky U, Vargas L, Florescu DF. Adenovirus: current epidemiology and emerging approaches to prevention and treatment. Curr Infect Dis Rep. 2014;16(8):416. doi:10.1007/s11908-014-0416-y
Yeung R, Eshaghi A, Lombos E, et al. Characterization of culture‐positive adenovirus serotypes from respiratory specimens in Toronto, Ontario, Canada: September 2007–June 2008. Virol J. 2009;6:11. doi:10.1186/1743-422X-6-11
Iii JPL, Kajon AE. Adenovirus: epidemiology, global spread of novel serotypes, and advances in treatment and prevention. Semin Respir Crit Care Med. 2016;37:586‐602. doi:10.1055/s-0036-1584923
Al‐Heeti OM, Cathro HP, Ison MG. Adenovirus infection and transplantation. Transplantation. 2022;106(5):920‐927. doi:10.1097/TP.0000000000003988
Feuchtinger T, Lang P, Handgretinger R. Adenovirus infection after allogeneic stem cell transplantation. Leuk Lymphoma. 2007;48:244‐255. doi:10.1080/10428190600881157
Hiwarkar P, Gaspar HB, Gilmour K, et al. Impact of viral reactivations in the era of pre‐emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients. Bone Marrow Transplant. 2013;48(6):803‐808. doi:10.1038/bmt.2012.221
Kainulainen L, Nikoskelainen J, Vuorinen T, Tevola K, Liippo K, Ruuskanen O. Viruses and bacteria in bronchial samples from patients with primary hypogammaglobulinemia. Am J Respir Crit Care Med. 1999;159(4 Pt 1):1199‐1204. doi:10.1164/ajrccm.159.4.9807067
Kainulainen L, Vuorinen T, Rantakokko‐Jalava K, Österback R, Ruuskanen O. Recurrent and persistent respiratory tract viral infections in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol. 2010;126(1):120‐126. doi:10.1016/j.jaci.2010.04.016
Schultz KAP, Neglia JP, Smith AR, Ochs HD, Torgerson TR, Kumar A. Familial hemophagocytic lymphohistiocytosis in two brothers with X‐linked agammaglobulinemia. Pediatr Blood Cancer. 2008;51(2):293‐295. doi:10.1002/pbc.21573
Mellon G, Henry B, Aoun O, et al. Adenovirus related lymphohistiocytic hemophagocytosis: case report and literature review. J Clin Virol. 2016;78:53‐56. doi:10.1016/j.jcv.2016.03.011
Seidel MG, Kastner U, Minkov M, Gadner H. IVIG treatment of adenovirus infection‐associated macrophage activation syndrome in a two‐year‐old boy: case report and review of the literature. Pediatr Hematol Oncol. 2003;20(6):445‐451.
Lion T. Adenovirus persistence, reactivation, and clinical management. FEBS Lett. 2019;593(24):3571‐3582. doi:10.1002/1873-3468.13576
Alligon M, Mahlaoui N, Courteille V, et al. An appraisal of the frequency and severity of noninfectious manifestations in primary immunodeficiencies: a study of a national retrospective cohort of 1375 patients over 10 years. J Allergy Clin Immunol. 2022;149(6):2116‐2125. doi:10.1016/j.jaci.2021.12.790
Pérot P, Fourgeaud J, Rouzaud C, et al. Circovirus hepatitis infection in heart‐lung transplant patient, France. Emerg Infect Dis. 2023;29(2):286‐293. doi:10.3201/eid2902.221468
Neven B, Pérot P, Bruneau J, et al. Cutaneous and visceral chronic granulomatous disease triggered by a rubella virus vaccine strain in children with primary immunodeficiencies. Clin Infect Dis. 2017;64(1):83‐86. doi:10.1093/cid/ciw675
Winter S, Lechapt E, Gricourt G, et al. Fatal encephalitis caused by Newcastle disease virus in a child. Acta Neuropathol. 2021;142(3):605‐608. doi:10.1007/s00401-021-02344-w
Fuss IJ, Friend J, Yang Z, et al. Nodular regenerative hyperplasia in common variable immunodeficiency. J Clin Immunol. 2013;33(4):748‐758. doi:10.1007/s10875-013-9873-6
Malamut G, Ziol M, Suarez F, et al. Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities. J Hepatol. 2008;48(1):74‐82. doi:10.1016/j.jhep.2007.08.011
Ramlaul N, Ooi J, Jeffrey GP, et al. Liver transplantation in adults with liver disease due to common variable immunodeficiency leads to early recurrent disease and poor outcome. Liver Transpl. 2018;24(11):1622‐1626. doi:10.1002/lt.25343
Ward C, Lucas M, Piris J, Collier J, Chapel H. Abnormal liver function in common variable immunodeficiency disorders due to nodular regenerative hyperplasia. Clin Exp Immunol. 2008;153(3):331‐337. doi:10.1111/j.1365-2249.2008.03711.x
Daniels JA, Torbenson M, Vivekanandan P, Anders RA, Boitnott JK. Hepatitis in common variable immunodeficiency. Hum Pathol. 2009;40(4):484‐488. doi:10.1016/j.humpath.2008.09.008
Zhang SY, Zhang Z, Fu JL, et al. Progressive CD127 down‐regulation correlates with increased apoptosis of CD8 T cells during chronic HIV‐1 infection. Eur J Immunol. 2009;39(5):1425‐1434. doi:10.1002/eji.200839059
Carrette F, Surh CD. IL‐7 signaling and CD127 receptor regulation in the control of T cell homeostasis. Semin Immunol. 2012;24(3):209‐217. doi:10.1016/j.smim.2012.04.010
Hercun J, Parikh E, Kleiner DE, et al. Recurrent nodular regenerative hyperplasia following liver transplantation in common variable immunodeficiency. Hepatology. 2021;74(3):1698‐1701. doi:10.1002/hep.31775
Bonatti HJR, Roman AL, Krebs E, et al. Good long‐term outcome following liver transplant in a patient with common variable immunodeficiency syndrome despite multiple infections and recurrent nodular regenerative hyperplasia. Exp Clin Transplant. 2023;21(1):66‐69. doi:10.6002/ect.2022.0067
Carter CRD, Aravind G, Smalle NL, Cole JY, Savic S, Wood PMD. CVID patients with autoimmunity have elevated T cell expression of granzyme B and HLA‐DR and reduced levels of Treg cells. J Clin Pathol. 2013;66(2):146‐150. doi:10.1136/jclinpath-2012-201046
Klocperk A, Friedmann D, Schlaak AE, et al. Distinct CD8 T cell populations with differential exhaustion profiles associate with secondary complications in common variable immunodeficiency. J Clin Immunol. 2022;42(6):1254‐1269. doi:10.1007/s10875-022-01291-9
Szablewski V, René C, Costes V. Indolent cytotoxic T cell lymphoproliferation associated with nodular regenerative hyperplasia: a common liver lesion in the context of common variable immunodeficiency disorder. Virchows Arch Int J Pathol. 2015;22:733‐740. doi:10.1007/s00428-015-1862-0
Ruohtula T, Kondrashova A, Lehtonen J, et al. Immunomodulatory effects of rhinovirus and enterovirus infections during the first year of life. Front Immunol. 2021;11:567046. doi:10.3389/fimmu.2020.567046
Maisch B, Richter A, Hufnagel G, et al. Abstract 20154: intravenous Pentaglobin eradicates inflammation and reduces viral load in Parvo B19 and adenovirus positive myocarditis. Circulation. 2010;122(Suppl_21):A20154. doi:10.1161/circ.122.suppl_21.A20154